The H-2 isoantigenicity of murine tissues was unaffected by the intraperitoneal growth of the Ehrlich ascites tumor, as shown by their normal capacity to absorb H-2 isohemagglutinins. Skin grafts from Ehrlich ascites tumor-bearing C57BL mice had a longer survival in RIII mice than grafts from nor mal donors. First-set allografts from tumor-bearing donors effectively immunized the hosts against second-set allografts from normal donors. Second-set allografts from tumor-bearing mice showed a prolonged survival in mice presensitized by firstset allografts from either normal or tumor-bearing donors. It therefore seems that the prolonged survival of skin allografts from tumor-bearing donors is not due to their decreased antigenicity or deficient immunogenicity, but rather to their in creased resistance to the allograft reaction of the host.
INTRODUCTION
Skin grafts from cancer patients survive longer than grafts from normal donors in both cancer patients (9) and in normal recipients (2) . Similarly, skin grafts obtained from mice bearing ascites tumors (4) or other types of tumors (7) show a pro longed survival in allogeneic hosts.
The aim of the present study was to elucidate the mechanism underlying this phenomenon. The antigenicity of the tissues of tumor-bearing animals was assayed by determining their ca pacity to absorb isohemagglutinins in vitro. First-and secondset skin allografts from normal and tumor-bearing animals were examined to determine whether the skin of tumor-bearing animals showed either decreased immunogenicity or increased resistance to the allograft reaction.
MATERIALS AND METHODS

Mice
All mice belonged to inbred strains bred at the Department of Experimental Medicine and Cancer Research. Male mice of the C57BL/6 strain served as donors of skin grafts, while Kill/Jem mice of the same sex served as recipients. For some of the serologie tests mice of the C3H/An and A strains were used.
Tumor
Five million Ehrlich ascites tumor cells were injected intrapcritoneally into C57BL/6 mice one week before their skin was used for grafting or their tissues were analyzed serologically.
Skin Grafts
Full-thickness skin grafts were sutured with 4-0 silk sutures and dressed with a sterile layer of vaseline-gauze, followed bypressure dressing. Each recipient was kept in a separate cage. The dressings were removed on the 5th postoperative day, and the grafts examined daily by two observers. Second-set grafts were applied two to three weeks after the first grafts.
The criteria for graft rejection were scale formation, drying and hardening of the grafts, or black discoloration and necrosis of 80-100% of the surface of the graft,
Serologie Technics
Isoantisera were prepared by repeated intraperitoneal injec tions of C57BL spleen cells to C3H mice and of A spleen cells into C57BL mice. One week after the last injection, mice were bled from the retroorbital sinus through a glass capillary. Sera were stored at â€"20Â°C.
Isohemagglutinins were determined according to the modifi cation by Amos (1) of the dextran-human serum method of Gorer and Mikulska (6) .
Tissues used for absorption were homogenized with cold nor mal saline, 1.0 gm tissue per 1.0 ml saline; the tissue-mince was stored at â€"20Â°C until used.
Method of Absorption
The H-2 isoantigenicity of murine tissues was assayed by determining their capacity to absorb isohemagglutinins accord ing to a technic described previously (10) .
Serial dilutions of 0.025 ml antiserum were prepared in 6 x 50 mm test tubes, and an equal volume of tissue-mince was added to each tube. The test tubes were left at room tempera ture for 1 hour, shaken from time to time, and then centrifuged at 3,000 rpm for 5 minutes. The supernatant was tested for the presence of hemagglutinins. In each absorption experiment the lowest antiserum dilution that was still absorbed completely by the tissue preparation was determined. Distribution of H-2 isoantigenic activity in tissues of normal and tumor-bearing C57BL and A mice.
"Each value represents the result of one absorption experi ment.
Antigen Units
One unit of antibody was defined as that amount of antibody in a volume of 0.025 ml that would just cause macroscopic agglutination of red blood cells. Due to the 2-fold dilution in the absorption procedure, one unit of antigen was defined as the antigenic activity of 0.025 ml of tissue-mince that would absorb completely two units of antibody (cf. 10). Accordingly, using an antiserum with a hemagglutination titer of 1024, a tissue-mince that absorbed completely a 1:16 serum dilution (containing 64 antibody units) was defined as having 32 units of antigen.
RESULTS
Survival of Skin Allografts from Normal and Tumor-bearing
Donors
The survival time of first-set allografts from tumor-bearing donors was only slightly longer than that of grafts from normal mice (Table 1 ), but the difference was statistically significant (P < 0.02).
Second-set skin allografts from normal donors showed a sim ilar accelerated rejection in animals having received first-set grafts from either normal or tumor-bearing donors (Table 1 , Groups 4 and 6). Since there was no significant difference be tween the survival of second-set grafts in these two groups, it seems that the first-set graft derived from tumor-bearing an imals had an immunizing capacity similar to that of grafts from normal donors.
In mice immunized by first-set allografts from normal donors the survival of second-set grafts from tumor-bearing animals was significantly greater than that of second-set grafts from normal donors (Table 1 , Groups 3 and 4) (P < 0.001). A sig nificantly prolonged survival of second-set skin grafts from tu mor-bearing donors, as compared to second-set grafts from normal donors, was also evident in recipients who had received first-set grafts from tumor-bearing donors (Table 1 , Groups 5 and 6) (P < 0.005).
Serologie Absorption Experiments
The intraperitoneal growth of the Ehrlich ascites tumor pro duced no detectable change in the capacity of various murine tissues to absorb H-2 isohemagglutinins ( Table 2 ). The antigenicity of the tissues examined in the present study was sim ilar to that previously found in normal mice (3, 10) .
DISCUSSION
It was found previously that, when skin from normal and from cancer patients was grafted simultaneously to other can cer patients, the grafts derived from cancer patients showed a prolonged survival (9). Amos et al. (2) noted a prolonged survival of skin allografts derived from cancer patients in nor mal recipients. Similar to the findings in man, skin grafts from mice bearing various types of tumors had a prolonged survival in allogeneic hosts (4, 7, 8) .
Several factors could account for the prolonged survival of grafts from tumor-bearing donors: (a) decreased antigenicity, i.e., decreased concentration of antigens in the tissue grafted; (b) decreased immunogenicity, i.e., deficient capacity of the grafts to elicit an immune response; and (c) increased re sistance of the grafts to the allograft reaction of the host.
In the present study, serologie absorption experiments failed to show any decrease of the H-2 isoantigenicity in various tis sues of tumor-bearing mice. Similarly, cytotoxicity tests did not reveal any decrease in the concentration of the H-2 isoanti genicity of the spleen and thymus cells of tumor-bearing mice (12) . Since in the present study skin of tumor-bearing animals was not analyzed serologically it could be argued that, in con trast to other tissues, skin might have undergone antigenic changes. However, this possibility seems unlikely, in view of the fact that the skin of tumor-bearing mice showed no evi dence of decreased immunogenicity. Skin allografts from tumorbearing animals curtailed the survival of second-set allografts to the same extent as skin grafts from normal mice.
There was thus no evidence for decreased antigenicity or for decreased immunogenicity of tissues of tumor-bearing animals. There was, however, evidence that skin grafts obtained from tumor-bearing donors had an increased resistance to the allo graft reaction. This was clearly shown by the prolonged sur vival of second-set grafts from tumor-bearing donors in hosts preimmunized by first-set allografts from either normal or tu mor-bearing donors.
Various physiologic alterations in the tumor-bearing organism could render its tissues less susceptible to the allograft reaction (cf. 11). The increased secretion of corticostcroid hormones in tumor-bearing hosts could lead to stabilization of cell and lyso-MARCH 1968 some membranes (13) and thus increase the resistance of the tissues. Alternatively, the anemia of tumor-bearing organisms could lead to acclimatization of the tissues to hypoxia, and render them less susceptible to the adverse effects of the allograft reaction (cf. 5).
